Literature DB >> 29234629

Lenvatinib in Advanced Hepatocellular Carcinoma.

Masatoshi Kudo1.   

Abstract

Entities:  

Year:  2017        PMID： 29234629      PMCID： PMC5704706          DOI： 10.1159/000479573

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  23 in total

1.  Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials.

Authors:  Richard Jackson; Eftychia-Eirini Psarelli; Sarah Berhane; Harun Khan; Philip Johnson
Journal:  J Clin Oncol       Date:  2017-01-03       Impact factor: 44.544

2.  Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2016-12-15       Impact factor: 11.740

3.  Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2015-09-11       Impact factor: 11.740

4.  Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib.

Authors:  Takeshi Terashima; Tatsuya Yamashita; Noboru Takata; Hidetoshi Nakagawa; Tadashi Toyama; Kuniaki Arai; Kazuya Kitamura; Taro Yamashita; Yoshio Sakai; Eishiro Mizukoshi; Masao Honda; Shuichi Kaneko
Journal:  Hepatol Res       Date:  2015-11-02       Impact factor: 4.288

5.  Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Deng-Yn Lin; Joong-Won Park; Masatoshi Kudo; Shukui Qin; Hyun-Cheol Chung; Xiangqun Song; Jianming Xu; Guido Poggi; Masao Omata; Susan Pitman Lowenthal; Silvana Lanzalone; Liqiang Yang; Maria Jose Lechuga; Eric Raymond
Journal:  J Clin Oncol       Date:  2013-09-30       Impact factor: 44.544

6.  Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.

Authors:  Masafumi Ikeda; Takuji Okusaka; Shuichi Mitsunaga; Hideki Ueno; Toshiyuki Tamai; Takuya Suzuki; Seiichi Hayato; Tadashi Kadowaki; Kiwamu Okita; Hiromitsu Kumada
Journal:  Clin Cancer Res       Date:  2015-10-23       Impact factor: 12.531

7.  SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

Authors:  Andrew X Zhu; Olivier Rosmorduc; T R Jeffry Evans; Paul J Ross; Armando Santoro; Flair Jose Carrilho; Jordi Bruix; Shukui Qin; Paul J Thuluvath; Josep M Llovet; Marie-Aude Leberre; Markus Jensen; Gerold Meinhardt; Yoon-Koo Kang
Journal:  J Clin Oncol       Date:  2014-12-29       Impact factor: 44.544

8.  Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.

Authors:  Osamu Tohyama; Junji Matsui; Kotaro Kodama; Naoko Hata-Sugi; Takayuki Kimura; Kiyoshi Okamoto; Yukinori Minoshima; Masao Iwata; Yasuhiro Funahashi
Journal:  J Thyroid Res       Date:  2014-09-10

9.  Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.

Authors:  Yuji Yamamoto; Junji Matsui; Tomohiro Matsushima; Hiroshi Obaishi; Kazuki Miyazaki; Katsuji Nakamura; Osamu Tohyama; Taro Semba; Atsumi Yamaguchi; Sachi Suzuki Hoshi; Fusayo Mimura; Toru Haneda; Yoshio Fukuda; Jun-Ichi Kamata; Keiko Takahashi; Masayuki Matsukura; Toshiaki Wakabayashi; Makoto Asada; Ken-Ichi Nomoto; Tatsuo Watanabe; Zoltan Dezso; Kentaro Yoshimatsu; Yasuhiro Funahashi; Akihiko Tsuruoka
Journal:  Vasc Cell       Date:  2014-09-06

10.  Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.

Authors:  Toshiyuki Tamai; Seiichi Hayato; Seiichiro Hojo; Takuya Suzuki; Takuji Okusaka; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Clin Pharmacol       Date:  2017-05-31       Impact factor: 3.126
View more
  21 in total

1.  Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-08-24       Impact factor: 11.740

2.  Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-02-15       Impact factor: 11.740

Review 3.  Implications of Immunotherapy in Hepatobiliary Tumors.

Authors:  Aline Gottlieb; Jan Best; Ali Canbay
Journal:  Visc Med       Date:  2019-02-08

Review 4.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

Review 5.  Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies.

Authors:  Christoph Roderburg; Burcin Özdirik; Alexander Wree; Münevver Demir; Frank Tacke
Journal:  Hepat Oncol       Date:  2020-05-28

6.  Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.

Authors:  Nikhil Chauhan; Janet Bukovcan; Eveline Boucher; David Cosgrove; Julien Edeline; Bonnie Hamilton; Laura Kulik; Fayaz Master; Riad Salem
Journal:  JMIR Res Protoc       Date:  2018-08-15

7.  Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion.

Authors:  Takako Nomura; Joji Tani; Akihiro Deguchi; Mai Nakahara; Kyoko Oura; Tomoko Tadokoro; Koji Fujita; Shima Mimura; Teppei Sakamoto; Asahiro Morishita; Hirohito Yoneyama; Hideki Kobara; Takayuki Sanomura; Yoshihiro Nishiyama; Keiichi Okano; Yasuyuki Suzuki; Shigeo Takahashi; Toru Shibata; Kunihiko Tsutsui; Takashi Himoto; Tsutomu Masaki
Journal:  Mol Clin Oncol       Date:  2019-09-09

8.  Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion.

Authors:  Haruhiko Takeda; Norihiro Nishijima; Akihiro Nasu; Hideyuki Komekado; Ryuichi Kita; Toru Kimura; Masatoshi Kudo; Yukio Osaki
Journal:  Hepatol Res       Date:  2019-01-31       Impact factor: 4.288

9.  Intravenous Injections of a Rationally Selected Oncolytic Herpes Virus as a Potent Virotherapy for Hepatocellular Carcinoma.

Authors:  Yong Luo; Chaolong Lin; Wenfeng Ren; Fei Ju; Zilong Xu; Huiling Liu; Zeng Yu; Jun Chen; Jun Zhang; Pingguo Liu; Chenghao Huang; Ningshao Xia
Journal:  Mol Ther Oncolytics       Date:  2019-10-01       Impact factor: 7.200

10.  Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway.

Authors:  Jianwen Hao; Qizhen Peng; Keruo Wang; Ge Yu; Yi Pan; Xiaoling Du; Na Hu; Xuening Zhang; Yu Qin; Huikai Li
Journal:  Biomed Res Int       Date:  2021-07-22       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.